Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

IMPAKT Breast Cancer Conference 2013 /
Early effect of PI3K-Akt-mTOR blockade on in vitro 18F-FDG uptake in HER2 breast cancer resistant to trastuzumab

2nd - 4th May 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.05.13
Views: 5037

Dr Yanina Dockx - University of Antwerp, Edegem, Belgium

ecancer reporter Peter Goodwin talks to Dr Yanina Dockx at the 2013 IMPAKT meeting in Brussels.

Aberrant activation of the PI3K-Akt-mTOR pathway is an important driver of resistance to HER2 targeted therapies and is involved in glucose homeostasis. 18F-FDG-PET has been proposed for early response assessment for targeted therapies, but knowledge on the effects of blocking this pathway on FDG uptake dynamics is limited.

The study investigated the effect of pharmacological PI3K-Akt-mTOR blockade on in vitro FDG uptake in HER2 breast cancer cells resistant to trastuzumab.

Blockade of PI3K-Akt-mTOR in trastuzumab resistant HER2 breast cancer was found to affect in vitro 18F-FDG uptake in transient and opposite ways, depending on the pharmacological target and duration of treatment.

Therefore, further validation is necessary to elucidate the cellular mechanisms involved in tracer uptake prior to routine clinical use for early response assessment.


ecancer's filming at IMPAKT has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation